Arrowhead Pharmaceuticals (ARWR) Stock Price Down 10.3%

Shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) traded down 10.3% during trading on Tuesday . The stock traded as low as $13.48 and last traded at $13.53. 1,755,886 shares changed hands during trading, a decline of 13% from the average session volume of 2,020,494 shares. The stock had previously closed at $15.09.

Several analysts recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, August 8th. BidaskClub lowered shares of Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 16th. Jefferies Financial Group restated a “buy” rating and set a $20.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, August 8th. Chardan Capital restated a “buy” rating and set a $17.50 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 13th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $25.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Thursday, October 4th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $21.45.

The stock has a market cap of $1.28 billion, a PE ratio of -28.79 and a beta of 2.05. The company has a current ratio of 8.69, a quick ratio of 8.69 and a debt-to-equity ratio of 0.02.

In other news, CEO Christopher Richard Anzalone sold 81,500 shares of Arrowhead Pharmaceuticals stock in a transaction dated Friday, November 9th. The shares were sold at an average price of $14.39, for a total value of $1,172,785.00. Following the sale, the chief executive officer now owns 1,727,755 shares in the company, valued at $24,862,394.45. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Kenneth Allen Myszkowski sold 45,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $19.34, for a total transaction of $870,300.00. Following the completion of the sale, the chief financial officer now owns 335,815 shares in the company, valued at approximately $6,494,662.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 260,637 shares of company stock worth $3,850,343. Company insiders own 4.60% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. First Allied Advisory Services Inc. boosted its position in Arrowhead Pharmaceuticals by 5.5% during the second quarter. First Allied Advisory Services Inc. now owns 64,350 shares of the biotechnology company’s stock worth $875,000 after acquiring an additional 3,350 shares during the last quarter. Teachers Advisors LLC boosted its position in Arrowhead Pharmaceuticals by 2.5% during the third quarter. Teachers Advisors LLC now owns 170,714 shares of the biotechnology company’s stock worth $3,273,000 after acquiring an additional 4,191 shares during the last quarter. Blair William & Co. IL boosted its position in Arrowhead Pharmaceuticals by 7.0% during the third quarter. Blair William & Co. IL now owns 67,580 shares of the biotechnology company’s stock worth $1,296,000 after acquiring an additional 4,410 shares during the last quarter. AXA boosted its position in Arrowhead Pharmaceuticals by 16.5% during the third quarter. AXA now owns 35,300 shares of the biotechnology company’s stock worth $677,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Man Group plc boosted its position in Arrowhead Pharmaceuticals by 47.5% during the third quarter. Man Group plc now owns 16,785 shares of the biotechnology company’s stock worth $322,000 after acquiring an additional 5,408 shares during the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Arrowhead Pharmaceuticals (ARWR) Stock Price Down 10.3%” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/12/05/arrowhead-pharmaceuticals-arwr-stock-price-down-10-3.html.

About Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its medicines include ARO-HBV, a Phase I/II subcutaneous ribonucleic acid interference(RNAi) therapy candidate that is used for the treatment of chronic hepatitis B viral infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Recommended Story: Swap

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply